Shopping Cart
- Remove All
- Your shopping cart is currently empty
CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) with MMAE, targeting folate receptor (FRα) and TRPV6. It exhibits high binding affinity to FRα and low affinity to TRPV6. CBP-1008 shows antitumor activity and can be utilized for research in advanced solid tumors such as colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma, and follicular dendritic cell sarcoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) with MMAE, targeting folate receptor (FRα) and TRPV6. It exhibits high binding affinity to FRα and low affinity to TRPV6. CBP-1008 shows antitumor activity and can be utilized for research in advanced solid tumors such as colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma, and follicular dendritic cell sarcoma. |
In vitro | CBP-1008 demonstrates accelerated FRα-mediated internalization and cytotoxicity in the presence of TRPV6 compared to when TRPV6 is absent. |
In vivo | CBP-1008 accumulates and remains in tumors with a half-life exceeding 48 hours. The maximum tolerated dose (MTD) of CBP-1008 is 4 mg/kg in mice, 2 mg/kg in rats, and 1 mg/kg in monkeys. Its efficacy against FRα and TRPV6 positive ovarian PDX tumors surpasses that against ovarian PDX tumors with at least one negative marker, with tumor growth inhibition strongly correlated with IHC scores in FRα+/TRPV6+ tumors. |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.